Protocols
9 protocol(s) meet the specified criteria
PI: Weiss, Jared
Protocol No.TitleStatus
A8081001Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGRF Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer Open
CALGB30607Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer Open (affiliates only)
LCCC1509Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) not Eligible for Cisplatin TherapyOpen
LCCC1516A Phase II Trial of Sequential Consolidation with Pembrolizumab followed by Nab-paclitaxel after Standard First-Line Induction Chemotherapy in Advanced NSCLCOpen
LCCC1621Multimodality Therapy with induction Carboplatin/nab-Paclitaxel/Durvalumab followed by surgical resection followed by risk-adapted adjuvant therapy for the treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Open
LCCC1722CHART Intervention to Encourage Smoking Cessation During Treatment for Head/Neck Cancer: A Feasibility StudyOpen
LCCC1725A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab together with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Open
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
NCI9903A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase InhibitorOpen